Skip to content

Study · Non-randomized trial · 2022

2 results

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9624830 (opens in a new tab)PepBankPUB-99180903
Read at sourceSource pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with POMC, PCSK1, or LEPR biallelic deficiency, setmelanotide continued to reduce body weight and BMI.

    In plain wordsIn patients with these genetic deficiencies, body weight and BMI continued to decrease during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    DecreaseBody weight and BMI
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Setmelanotide treatment continued to provide sizable reductions in body weight and body mass index while being generally well tolerated.
    1 context sentence
    Summary · context
    The present study aims to examine the long-term efficacy of ∼3 years of setmelanotide treatment in patients with POMC, PCSK1, and LEPR biallelic deficiency in a long-term extension after a previous trial.
  2. 02HumanNon-randomized trialSafety outcome

    In patients with POMC, PCSK1, or LEPR biallelic deficiency, long-term setmelanotide was generally well tolerated.

    In plain wordsIn patients with these genetic deficiencies, long-term setmelanotide was generally well tolerated.

    Peptide
    Setmelanotide
    Outcome
    Not applicableTolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Setmelanotide treatment continued to provide sizable reductions in body weight and body mass index while being generally well tolerated.
    1 context sentence
    Summary · context
    The present study aims to examine the long-term efficacy of ∼3 years of setmelanotide treatment in patients with POMC, PCSK1, and LEPR biallelic deficiency in a long-term extension after a previous trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.